Skip to content

aTyr Pharma ATYR Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$16.43M+2.6%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$32.44M+1.5%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's free cash flow?
aTyr Pharma (ATYR) reported free cash flow of -$12.66M in Q1 2026.
How has aTyr Pharma's free cash flow changed year-over-year?
aTyr Pharma's free cash flow increased by 17.9% year-over-year, from -$15.42M to -$12.66M.
What is the long-term trend for aTyr Pharma's free cash flow?
Over 4 years (2021 to 2025), aTyr Pharma's free cash flow has grown at a 16.9% compound annual growth rate (CAGR), from -$33.27M to -$62.06M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.